ArticleBritish journal of cancer2005
Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.Human reproduction update · 2026Pooled it
- Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.Epidemiologic reviews · 2014Pooled it
- Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial.The Lancet regional health. Europe · 2025Article
- Replacement with sex steroids in hypopituitary men and women: implications for gender differences in morbidities and mortality.Reviews in endocrine & metabolic disorders · 2024Review
- Changes in Rehmanniae Radix processing and their impact on ovarian hypofunction: potential mechanisms of action.Frontiers in pharmacology · 2024Review
- Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020Review
- Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency.Frontiers in endocrinology · 2020Review
- Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer.Breast cancer (Dove Medical Press) · 2019Article
- Screening breast magnetic resonance imaging in women with hormone replacement therapy.European journal of medical research · 2018Article
- Article
- HRT for women with premature ovarian insufficiency: a comprehensive review.Human reproduction open · 2017Review
- Premature ovarian insufficiency: the context of long-term effects.Journal of endocrinological investigation · 2016Review
- Hormone therapy and young-onset breast cancer.American journal of epidemiology · 2015Article
- Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study.British journal of clinical pharmacology · 2015Article
- Space-time clusters of breast cancer using residential histories: a Danish case-control study.BMC cancer · 2014Article
- Hormonal contraceptive use and breast cancer in Thai women.Journal of epidemiology · 2014Article
- Hormone replacement therapy and the risk of breast cancer.Nature reviews. Clinical oncology · 2011Review
- Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.British journal of cancer · 2011Article
- Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.Breast cancer research : BCR · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies and meta-analyses have shown that hormone replacement therapy (HRT) for menopausal symptoms increases the risk of developing breast cancer, estimated to be 2.3% for each year of use. The influence of different oestrogen-progestin regimens has still not been fully evaluated. Using longitudinal data from the population-based prescription database of the county of North Jutland, Denmark, and the Danish Cancer Registry, we examined the risk of developing breast cancer in relation to HRT in a cohort of 78,380 women aged 40-67 years from 1989 to 2002. A total of 1462 cases of breast cancer were identified during a mean follow-up of 10 years. Use of HRT did not increase the risk of breast cancer in women aged 40-49 years. Restricting the cohort to 48,812 women aged 50 years or more at entry, of whom 15 631 were HRT users, we found an increased risk associated with current use of HRT (relative risk 1.61, 95% confidence interval 1.38-1.88). The risk increased with increasing duration of use and decreased with time since last HRT prescription, reaching unity after 5 years. No material risk difference was observed among the various HRT-regimens. This population-based cohort study provides further confirmation that HRT increases the risk of developing breast cancer in women aged 50 years or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.